Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday. Michael Cherny has ...

Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company ...

The number of bird flu cases has risen to 31 in the U.S. but there is no evidence of person-to-person transmission, the CDC ...

The firm's QScout CBC diagnostic system is intended to deliver faster complete blood count test results and detect severe infection earlier.

Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS. Read why I ...